Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

Biotech & Pharma

3 articles

Novo Nordisk Exits Internal Parkinson's Research, Handing Discovery to AI Partner as NVIDIA's BioNeMo Becomes Global Pharma Infrastructure

Novo Nordisk Exits Internal Parkinson's Research, Handing Discovery to AI Partner as NVIDIA's BioNeMo Becomes Global Pharma Infrastructure

Novo Nordisk has licensed its Parkinson's cell therapy program to Cellular Intelligence and closed its internal discovery unit—a structural shift mirrored by pharma companies worldwide. NVIDIA's BioNeMo platform has made AI drug discovery operational infrastructure, not experimental technology. NVO shares rose 25% in a month as markets price in AI-native pipelines as durable competitive advantages.

LM Salvado•
Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar

Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar

Six or more FDA PDUFA decisions are expected in 2026 covering antibody-drug conjugates, checkpoint inhibitors, and precision molecules — the densest oncology approval calendar in years. AbbVie's EHA 2026 data showed venetoclax plus obinutuzumab delivered a median eight years to next treatment in untreated CLL. A Century Therapeutics iPSC cell therapy for type 1 diabetes, affecting nine million people globally, extends the catalyst window into Q1 2027.

LM Salvado•
Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

A wave of antibody-drug conjugate combination trials across the US and China is converging on a narrow 2026–2027 regulatory window. China's NMPA has already approved a fruquintinib-sintilimab combination for renal cell carcinoma, validating the global strategy. Portfolio managers holding multiple names in this cluster face correlated binary-event risk in the second half of 2026.

LM Salvado•